Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
LYEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $209.76M
- EPS (TTM)
- -$12.86
- Dividend yield
- None
- 52-week range
- 8.38 – 45.00
- Day range
- 8.38 – 8.93
- Volume / Avg
- 184.67K / 144.17K
- Beta
- —
- Shares outstanding
- 24.51M
- Next earnings
- Nov 6, 2026
52-week range
LYEL stock today
On Oct 7, LYEL ended the session at $8.56, shedding $0.05 (0.58%), versus the S&P 500's 0.22% decline. At this level, LYEL sits near the bottom of its 52-week range of $8.38 to $45.00: 81.0% below the high, set on Dec 22, 2025 and 2.1% above the low. LYEL is down 72.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 51.6%.
Lyell Immunopharma has posted a net loss over the last twelve months (EPS of -$12.86), so its P/E ratio is not meaningful. Lyell Immunopharma's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Lyell Immunopharma
Company profileLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Lynn Seely M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 161
- IPO year
- 2021
- Website
- lyell.com
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$37.88+342.52%
- Strong buy 2
- Buy 5
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
Lyell Immunopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SIONSionna Therapeutics Inc. | 4.82 | +1.47% | $217.62M | vs LYEL |
| TRDAEntrada Therapeutics Inc. | 5.61 | +3.51% | $218.43M | vs LYEL |
| RNACCartesian Therapeutics Inc. | 6.68 | -1.04% | $202.11M | vs LYEL |
| NATRNature's Sunshine Products Inc. | 12.59 | +0.40% | $221.53M | vs LYEL |
| KROSKeros Therapeutics Inc. | 11.21 | +1.82% | $222.26M | vs LYEL |
| ELDNEledon Pharmaceuticals Inc. | 2.42 | -1.22% | $196.65M | vs LYEL |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs LYEL |
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs LYEL |
Indexes, lists and sector
Lyell Immunopharma stock FAQ
What is Lyell Immunopharma's stock price today?
LYEL last traded at $8.56 as of Oct 7, 4:00 PM EDT, down 0.58% on the day. Prices are delayed at least 15 minutes.
Does Lyell Immunopharma pay a dividend?
No. Lyell Immunopharma does not currently pay a regular cash dividend.
When is Lyell Immunopharma's next earnings date?
Lyell Immunopharma is expected to report earnings on Friday, November 6, 2026.
Who is Lyell Immunopharma's CEO?
Dr. Lynn Seely M.D., Ph.D. is the chief executive officer of Lyell Immunopharma Inc., which has about 161 employees.
Has LYEL ever split its stock?
Yes. The most recent LYEL stock split was a 1-for-20 split on Jun 2, 2025.
What is the LYEL 52-week high?
The 52-week high for LYEL is $45.00 and the 52-week low is $8.38. The stock is currently 81.0% below its high.